Acumen Pharmaceuticals, Inc. (ABOS)
0.2432
+0.02
(+8.81%)
USD |
NASDAQ |
Nov 09, 11:58
Acumen Pharmaceuticals Net Income (Quarterly) : -25.37M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -25.37M |
| June 30, 2026 | -32.72M |
| March 31, 2026 | -20.74M |
| December 31, 2025 | -25.14M |
| September 30, 2025 | -26.45M |
| June 30, 2025 | -40.95M |
| March 31, 2025 | -28.80M |
| December 31, 2024 | -37.15M |
| September 30, 2024 | -29.76M |
| June 30, 2024 | -20.54M |
| March 31, 2024 | -14.87M |
| December 31, 2023 | -16.50M |
| September 30, 2023 | -12.96M |
| June 30, 2023 | -11.61M |
| Date | Value |
|---|---|
| March 31, 2023 | -11.31M |
| December 31, 2022 | -12.87M |
| September 30, 2022 | -10.71M |
| June 30, 2022 | -10.15M |
| March 31, 2022 | -9.129M |
| December 31, 2021 | -8.349M |
| September 30, 2021 | -3.902M |
| June 30, 2021 | -61.36M |
| March 31, 2021 | -27.00M |
| December 31, 2020 | -0.755M |
| September 30, 2020 | -2.49M |
| June 30, 2020 | -2.035M |
| March 31, 2020 | -2.045M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 14.16M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 25.37M |
| EPS Diluted (Quarterly) | -0.3508 |
| Enterprise Value | -36.13M |
| Earnings Yield | -635.9% |
| Normalized Earnings Yield | -639.19 |